Avalo Therapeutics (AVTX) Corporate presentation summary

Disease overview and market opportunity

• Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease affecting 1–4% of the global population, with significant tissue destruction and scarring.

• The HS therapeutics market is projected to exceed $10B globally by 2035, driven by increased diagnosis, treatment rates, and biologic adoption.

• Moderate-to-severe HS cases and biologic-treated patients are expected to grow substantially, with new approvals expanding patient access.

Study design and patient characteristics

• The Phase 2 LOTUS study evaluated abdakibart in moderate-to-severe HS, enrolling 253 patients randomized to two dosing regimens or placebo.

• Key inclusion criteria included ≥6 months of HS symptoms, ≥5 abscess/inflammatory nodules, and Hurley stage II or III lesions.

• Study completion rates were high across all arms, with balanced demographics and a significant proportion of patients with prior biologic exposure.

Efficacy results

• Abdakibart achieved a 42.5% combined HiSCR75 response at week 16, significantly higher than placebo (25.6%, p=0.004).

• HiSCR50 response rates were 61.7% for abdakibart versus 40.7% for placebo (p=0.0009), with consistent efficacy across doses and prior biologic exposure.

• Improvements in HiSCR75 were observed as early as week 4 and sustained through week 16.

• Secondary endpoints, including flare rate, abscess/nodule count, and pain reduction, were statistically significant or numerically favorable.

• Early and sustained decreases in disease severity (IHS4) and draining tunnel count were seen in both treatment groups.